DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://www.nature.com/articles/nrd3144, but it redirected us to https://www.nature.com/articles/nrd3144. The analysis below is for the second page.

Title[redir]:
Anticancer drug development: the grand challenges | Nature Reviews Drug Discovery
Description:
Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?

Matching Content Categories {📚}

Science
Education
Social Networks

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,420 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

nature, drug, access, article, research, cell, development, cookies, content, open, privacy, discovery, cancer, data, reviews, anticancer, hait, breast, scientific, author, advertising, information, subscribe, challenges, william, oncology, institution, articles, evaluation, imaging, screening, reports, buy, permissions, optional, media, personal, parties, policy, journals, log, journal, comment, april, grand, cite, treatment, manufacture, herpositive, immunotoxin,

Topics {✒️}

nature portfolio permissions reprints privacy policy advertising nature social media anchorage-independent cell growth research advances anticancer drug development springerlink instant access author information authors drug discovery effectiveness personal data data protection permissions author declares competing financial interests privacy cell imaging author explore content subscription content lung cancer european economic area access heterogeneous tissue distribution institutional subscriptions read offered helpful comments senior vice president enaminone-grafted trithiocarbonate accepting optional cookies journals search log manage preferences biological screening content article hait development grand challenges william institution subscribe issue learn institution buy article purchase optional cookies choices article cite essential cookies cookies skip journal publish subscribe sign potential anticancer

Questions {❓}

What are the key challenges in anticancer drug development, and how might they be addressed?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Anticancer drug development: the grand challenges
         description:Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?
         datePublished:
         dateModified:
         pageStart:253
         pageEnd:254
         sameAs:https://doi.org/10.1038/nrd3144
         keywords:
            Drug development
            Drug regulation
            Biomedicine
            general
            Pharmacology/Toxicology
            Biotechnology
            Medicinal Chemistry
            Molecular Medicine
            Cancer Research
         image:
         isPartOf:
            name:Nature Reviews Drug Discovery
            issn:
               1474-1784
               1474-1776
            volumeNumber:9
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:William N. Hait
               affiliation:
                     name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected]
                     address:
                        name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected] ,
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Anticancer drug development: the grand challenges
      description:Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?
      datePublished:
      dateModified:
      pageStart:253
      pageEnd:254
      sameAs:https://doi.org/10.1038/nrd3144
      keywords:
         Drug development
         Drug regulation
         Biomedicine
         general
         Pharmacology/Toxicology
         Biotechnology
         Medicinal Chemistry
         Molecular Medicine
         Cancer Research
      image:
      isPartOf:
         name:Nature Reviews Drug Discovery
         issn:
            1474-1784
            1474-1776
         volumeNumber:9
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:William N. Hait
            affiliation:
                  name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected]
                  address:
                     name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected] ,
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Drug Discovery
      issn:
         1474-1784
         1474-1776
      volumeNumber:9
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected]
      address:
         name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected] ,
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:William N. Hait
      affiliation:
            name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected]
            address:
               name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected] ,
               type:PostalAddress
            type:Organization
PostalAddress:
      name:William N. Hait, M.D., Ph.D., is Senior Vice President and Worldwide Head at Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA. [email protected] ,
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(97)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Prism.js
Zoom.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

3.98s.